Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 14/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.31 |
| ▸ | FAP | Q12884 | 2/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.30 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL332198 | 0.98 | MGLL (0.35) | MGLLDPP4LIPGBRD4DPP8 | |
| Hydrochloric Acid SCHEMBL3841448 | 0.89 | DPP4 (0.33) | MGLLDPP4LIPGBRD4DPP8 | |
| SCHEMBL19005845 | 0.86 | MGLL (0.37) | MGLLLIPG | |
| SCHEMBL1971368 | 0.86 | MGLL (0.34) | MGLLDPP4LIPGDPP8DPP7 | |
| SCHEMBL3841455 | 0.84 | DPP4 (0.34) | DPP4BRD4DPP8FAPHTR2A | |
| SCHEMBL32679285 | 0.82 | — | — | |
| SCHEMBL13093275 | 0.81 | MGLL (0.33) | MGLL | |
| SCHEMBL19005247 | 0.79 | MGLL (0.34) | MGLL | |
| Hydrochloric Acid SCHEMBL573084 | 0.77 | MGLL (0.34) | MGLL | |
| SCHEMBL4244840 | 0.76 | MGLL (0.31) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 677 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930453-A | Sitagliptin intermediate and preparation method thereof | 浙江九洲药业股份有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119335072-A | Detection method of hydrazine compounds and application thereof | 广东东阳光药业股份有限公司 | 2025-01-21 | — | — | CN | claimed |
| CN-119086788-A | HPLC detection method for sitagliptin phosphate bulk drug and related substances thereof | 常州制药厂有限公司 | 2024-12-06 | — | — | CN | claimed |
| WO-2024119985-A1 | METHOD FOR PREPARING SITAGLIPTIN INTERMEDIATE PYRAZINE HYDROCHLORIDE | 台州达辰药业有限公司 | 2024-06-13 | — | — | WO | claimed |
| US-20240024312-A1 | PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-01-25 | — | — | US | claimed |
| CN-117003758-A | Preparation method for synthesizing sitagliptin | 南通常佑药业科技有限公司 | 2023-11-07 | — | — | CN | claimed |
| CN-113801903-B | Biosynthesis method of sitagliptin intermediate | 江苏八巨药业有限公司 | 2023-08-15 | — | — | CN | claimed |
| CN-116082342-A | Preparation method of sitagliptin intermediate pyrazine hydrochloride | 台州达辰药业有限公司 | 2023-05-09 | — | — | CN | claimed |
| WO-2023012819-A1 | RECOMBINANT TRANSAMINASE POLYPEPTIDES | QUANTUMZYME LLP (IN) | 2023-02-09 | — | — | WO | claimed |
| WO-2020109938-A1 | PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | DR. REDDY'S LABORATORIES LIMITED (IN) | 2020-06-04 | — | — | WO | claimed |
| US-8846916-B2 | Sitagliptin synthesis | GENERICS [UK] LIMITED (GB) | 2014-09-30 | — | — | US | claimed |
| WO-2014086325-A1 | A METHOD OF PREPARING 3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOIC ACID DERIVATIVES | ZENTIVA, K.S. (CZ) | 2014-06-12 | — | — | WO | claimed |
| WO-2014023930-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND INTERMEDIATE COMPOUNDS | CIPLA LIMITED (IN) | 2014-02-13 | — | — | WO | claimed |
| EP-2331545-B1 | IMPROVED PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE&NEW IMPURITIES IN PREPARATION THEREOF | CADILA HEALTHCARE LTD (IN) | 2013-10-02 | — | — | EP | claimed |
| WO-2013114173-A1 | A NOVEL PROCESS FOR THE PREPARATION OF SITAGLIPTIN | SMILAX LABORATORIES LIMITED (IN) | 2013-08-08 | — | — | WO | claimed |
| EP-2609099-A2 | SITAGLIPTIN, SALTS AND POLYMORPHS THEREOF | USV Limited (IN) | 2013-07-03 | — | — | EP | claimed |
| WO-2012025944-A2 | SITAGLIPTIN, SALTS AND POLYMORPHS THEREOF | USV LIMITED (IN) | 2012-03-01 | — | — | WO | claimed |
| EP-2423178-A1 | Process for the production of sitagliptin | Chemo Ibérica, S.A. (ES) | 2012-02-29 | — | — | EP | claimed |
| WO-2011102640-A2 | METHOD FOR PREPARING SITAGLIPTIN AND AMINE SALT INTERMEDIATES USED THEREIN | HANMI HOLDINGS CO., LTD. (KR) | 2011-08-25 | — | — | WO | claimed |
| WO-2010122578-A2 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS INTERMEDIATES | MSN LABORATORIES LIMITED (IN) | 2010-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024312-A1 | PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN | DPP4, NT5C, DPP7 | MGLL 3228/4885DPP4 1/4885LIPG 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.